{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:08:05Z","timestamp":1791472085370,"version":"4.3.4"},"reference-count":11,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["UEG Journal"],"published-print":{"date-parts":[[2026,4]]},"abstract":"ABSTRACT<\/jats:title>\n \n Background<\/jats:title>\n Intestinal tissue levels of infliximab (IFX) in patients with inflammatory bowel disease (IBD) treated with subcutaneous (SC) therapy have not been previously assessed.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To compare serum and colonic tissue IFX concentrations in IBD patients receiving SC versus intravenous (IV) IFX.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n This observational cross\u2010sectional study included IBD patients on stable SC or IV IFX maintenance therapy undergoing routine follow\u2010up colonoscopy. Clinical activity required elevated CDAI or Mayo score plus \u2265\u00a01 biomarker (fecal calprotectin >\u00a0250\u00a0\u03bcg\/g or CRP >\u00a05\u00a0mg\/L). Blood samples and two colonic biopsies were collected for serum and tissue IFX measurements.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Thirty\u2010five patients were included. Serum and tissue IFX concentrations were significantly higher in the SC versus IV group (22\u00a0\u03bcg\/mL vs. 9\u00a0\u03bcg\/mL,\n p<\/jats:italic>\n \u00a0<\u00a00.001; 25\u00a0\u03bcg\/g vs. 10\u00a0\u03bcg\/g,\n p<\/jats:italic>\n \u00a0=\u00a00.002). Serum and colonic tissue IFX levels were positively correlated in both cohorts (IV:\n r<\/jats:italic>\n \u00a0=\u00a00.42;\n p<\/jats:italic>\n \u00a0=\u00a00.014; SC:\n r<\/jats:italic>\n \u00a0=\u00a00.43;\n p<\/jats:italic>\n \u00a0=\u00a00.001). Colonic tissue IFX concentrations were higher in patients with mild\u2013moderate endoscopic activity than in those without active disease (\n p<\/jats:italic>\n \u00a0<\u00a00.001). Serum and colonic tissue IFX levels both predicted sustained clinical remission, with optimal thresholds of 14.5\u00a0\u03bcg\/mL (\n p<\/jats:italic>\n \u00a0=\u00a00.015) and 17\u00a0\u03bcg\/g (\n p<\/jats:italic>\n \u00a0<\u00a00.005), respectively. Colonic tissue IFX showed higher predictive accuracy (AUROC 0.82,\n p<\/jats:italic>\n \u00a0=\u00a00.01) than serum (AUROC 0.76,\n p<\/jats:italic>\n \u00a0=\u00a00.045).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n SC IFX achieved significantly higher serum and colonic tissue concentrations than IV IFX. Colonic tissue IFX levels demonstrated superior clinical relevance and may support future tissue\u2010based therapeutic drug monitoring strategies in IBD.<\/jats:p>\n <\/jats:sec>","DOI":"10.1002\/ueg2.70207","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T17:20:05Z","timestamp":1774459205000},"source":"Crossref","is-referenced-by-count":2,"title":["Higher Colonic Tissue Drug Concentrations of Subcutaneous Compared to Intravenous Administration of Infliximab Therapy in Patients With Inflammatory Bowel Disease"],"prefix":"10.1002","volume":"14","author":[{"given":"X.","family":"Roblin","sequence":"first","affiliation":[{"name":"Department of Gastroenterology University Hospital of Saint\u2010Etienne Saint\u2010Etienne France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Nancey","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology Lyon\u2010Sud Hospital Hospices Civils de Lyon University Claude Bernard Lyon 1 and CIRI (Centre International de Recherche en Infectiologie) INSERM U1111 Lyon France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Papamichael","sequence":"additional","affiliation":[{"name":"Center for Inflammatory Bowel Disease Division of Gastroenterology Beth Israel Deaconess Medical Centre Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Mechi","sequence":"additional","affiliation":[{"name":"Immunology Laboratory\/iBioThera CIC1408 University Hospital of Saint\u2010Etienne Saint\u2010Etienne France"},{"name":"CIRI Universit\u00e9 Claude Bernard Lyon 1 INSERM U1111, CNRS, UMR5308 ENS Lyon Universit\u00e9 Jean Monnet de Saint\u2010Etienne Saint\u2010Etienne France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Ouvrier\u2010Buffet","sequence":"additional","affiliation":[{"name":"Immunology Laboratory\/iBioThera CIC1408 University Hospital of Saint\u2010Etienne Saint\u2010Etienne France"},{"name":"CIRI Universit\u00e9 Claude Bernard Lyon 1 INSERM U1111, CNRS, UMR5308 ENS Lyon Universit\u00e9 Jean Monnet de Saint\u2010Etienne Saint\u2010Etienne France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. L.","family":"Charlois","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology Lyon\u2010Sud Hospital Hospices Civils de Lyon University Claude Bernard Lyon 1 and CIRI (Centre International de Recherche en Infectiologie) INSERM U1111 Lyon France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. S.","family":"Peaucelle","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology University Hospital of Saint\u2010Etienne Saint\u2010Etienne France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Bastide","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology University Hospital of Saint\u2010Etienne Saint\u2010Etienne France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. A.","family":"Berger","sequence":"additional","affiliation":[{"name":"Immunology Laboratory\/iBioThera CIC1408 University Hospital of Saint\u2010Etienne Saint\u2010Etienne France"},{"name":"CIRI Universit\u00e9 Claude Bernard Lyon 1 INSERM U1111, CNRS, UMR5308 ENS Lyon Universit\u00e9 Jean Monnet de Saint\u2010Etienne Saint\u2010Etienne France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Barrau","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology University Hospital of Saint\u2010Etienne Saint\u2010Etienne France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. S.","family":"Cheifetz","sequence":"additional","affiliation":[{"name":"Center for Inflammatory Bowel Disease Division of Gastroenterology Beth Israel Deaconess Medical Centre Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Duru","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology University Hospital of Saint\u2010Etienne Saint\u2010Etienne France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Paul","sequence":"additional","affiliation":[{"name":"Immunology Laboratory\/iBioThera CIC1408 University Hospital of Saint\u2010Etienne Saint\u2010Etienne France"},{"name":"CIRI Universit\u00e9 Claude Bernard Lyon 1 INSERM U1111, CNRS, UMR5308 ENS Lyon Universit\u00e9 Jean Monnet de Saint\u2010Etienne Saint\u2010Etienne France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,3,25]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.imbio.2019.09.008"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1611598"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmra0804647"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2021.02.068"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1080\/00365520701409035"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3462"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izae097"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl\u20102014\u2010308099"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/mib.0000000000001260"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2025.04.028"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.16852"}],"container-title":["United European Gastroenterology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ueg2.70207","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ueg2.70207","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ueg2.70207","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T08:03:22Z","timestamp":1780733002000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ueg2.70207"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,25]]},"references-count":11,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1002\/ueg2.70207"],"URL":"https:\/\/doi.org\/10.1002\/ueg2.70207","archive":["Portico"],"relation":{},"ISSN":["2050-6406","2050-6414"],"issn-type":[{"value":"2050-6406","type":"print"},{"value":"2050-6414","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,25]]},"article-number":"e70207"}}